Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

Saved in:
Bibliographic Details
Published in:Journal of Clinical and Experimental Hematopathology 2019, Vol.59(2), pp.98-100
Main Authors: Maruyama, Dai, Nagai, Hirokazu, Fukuhara, Noriko, Kitano, Toshiyuki, Ishikawa, Takayuki, Nishikawa, Tomoaki
Format: Article
Language:English
Subjects:
covalent BTK inhibitor
ibrutinib
Japanese patients
Letter to the Editor
mantle cell lymphoma
phase II clinical trial
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c529t-3e346ab7c695e8815c54f24c309267829ad954c345a7f36f07e15b33aca348d83
cites cdi_FETCH-LOGICAL-c529t-3e346ab7c695e8815c54f24c309267829ad954c345a7f36f07e15b33aca348d83
container_end_page 100
container_issue 2
container_start_page 98
container_title Journal of Clinical and Experimental Hematopathology
container_volume 59
creator Maruyama, Dai
Nagai, Hirokazu
Fukuhara, Noriko
Kitano, Toshiyuki
Ishikawa, Takayuki
Nishikawa, Tomoaki
description
doi_str_mv 10.3960/jslrt.19006
format article
fullrecord <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6661957</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_6661957</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-3e346ab7c695e8815c54f24c309267829ad954c345a7f36f07e15b33aca348d83</originalsourceid><addsrcrecordid>eNpVkEtLxDAQx4MoPlZPfoHcpWvSNGlzEUR8rAhe9BymaWqzpA-SrNJvb3ZXFrzM8zfDzB-ha0qWTApyuw7OxyWVhIgjdE6rimRS8vw4xawQWZFX5AxdhLAmpBBcsFN0xmjOS8bpOfJPdgCHIZk52IDHFgOeOggGr1Y4xE0zb2u29ptoB1tjO-BXmGAwiZggWjPEgH9s7LA3DqZgmltvWg86jn7GPQzRGayNc9jN_dSNPVyikxZcMFd_foE-nx4_Hl6yt_fn1cP9W6Z5LmPGTLoe6lILyU1VUa550eaFZkTmoqxyCY3kKS04lC0TLSkN5TVjoIEVVVOxBbrb7502dW8anS714NTkbQ9-ViNY9b8z2E59jd9KCEFl0meBbvYLtB9DSF8dZilRW-nVTnq1kz7R93t6HSJ8mQMLPlrtzB_Lpcq3Zjdz6OkOvDID-wWIfpDa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma</title><source>Open Access: PubMed Central</source><creator>Maruyama, Dai ; Nagai, Hirokazu ; Fukuhara, Noriko ; Kitano, Toshiyuki ; Ishikawa, Takayuki ; Nishikawa, Tomoaki</creator><creatorcontrib>Maruyama, Dai ; Nagai, Hirokazu ; Fukuhara, Noriko ; Kitano, Toshiyuki ; Ishikawa, Takayuki ; Nishikawa, Tomoaki</creatorcontrib><identifier>ISSN: 1346-4280</identifier><identifier>EISSN: 1880-9952</identifier><identifier>DOI: 10.3960/jslrt.19006</identifier><identifier>PMID: 31257351</identifier><language>eng</language><publisher>The Japanese Society for Lymphoreticular Tissue Research</publisher><subject>covalent BTK inhibitor ; ibrutinib ; Japanese patients ; Letter to the Editor ; mantle cell lymphoma ; phase II clinical trial</subject><ispartof>Journal of Clinical and Experimental Hematopathology, 2019, Vol.59(2), pp.98-100</ispartof><rights>2019 by The Japanese Society for Lymphoreticular Tissue Research</rights><rights>2019 by The Japanese Society for Lymphoreticular Tissue Research 2019 The Japanese Society for Lymphoreticular Tissue Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-3e346ab7c695e8815c54f24c309267829ad954c345a7f36f07e15b33aca348d83</citedby><cites>FETCH-LOGICAL-c529t-3e346ab7c695e8815c54f24c309267829ad954c345a7f36f07e15b33aca348d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661957/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661957/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Maruyama, Dai</creatorcontrib><creatorcontrib>Nagai, Hirokazu</creatorcontrib><creatorcontrib>Fukuhara, Noriko</creatorcontrib><creatorcontrib>Kitano, Toshiyuki</creatorcontrib><creatorcontrib>Ishikawa, Takayuki</creatorcontrib><creatorcontrib>Nishikawa, Tomoaki</creatorcontrib><title>Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma</title><title>Journal of Clinical and Experimental Hematopathology</title><addtitle>J Clin Exp Hematopathol</addtitle><subject>covalent BTK inhibitor</subject><subject>ibrutinib</subject><subject>Japanese patients</subject><subject>Letter to the Editor</subject><subject>mantle cell lymphoma</subject><subject>phase II clinical trial</subject><issn>1346-4280</issn><issn>1880-9952</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkEtLxDAQx4MoPlZPfoHcpWvSNGlzEUR8rAhe9BymaWqzpA-SrNJvb3ZXFrzM8zfDzB-ha0qWTApyuw7OxyWVhIgjdE6rimRS8vw4xawQWZFX5AxdhLAmpBBcsFN0xmjOS8bpOfJPdgCHIZk52IDHFgOeOggGr1Y4xE0zb2u29ptoB1tjO-BXmGAwiZggWjPEgH9s7LA3DqZgmltvWg86jn7GPQzRGayNc9jN_dSNPVyikxZcMFd_foE-nx4_Hl6yt_fn1cP9W6Z5LmPGTLoe6lILyU1VUa550eaFZkTmoqxyCY3kKS04lC0TLSkN5TVjoIEVVVOxBbrb7502dW8anS714NTkbQ9-ViNY9b8z2E59jd9KCEFl0meBbvYLtB9DSF8dZilRW-nVTnq1kz7R93t6HSJ8mQMLPlrtzB_Lpcq3Zjdz6OkOvDID-wWIfpDa</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Maruyama, Dai</creator><creator>Nagai, Hirokazu</creator><creator>Fukuhara, Noriko</creator><creator>Kitano, Toshiyuki</creator><creator>Ishikawa, Takayuki</creator><creator>Nishikawa, Tomoaki</creator><general>The Japanese Society for Lymphoreticular Tissue Research</general><general>JSLRT</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190101</creationdate><title>Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma</title><author>Maruyama, Dai ; Nagai, Hirokazu ; Fukuhara, Noriko ; Kitano, Toshiyuki ; Ishikawa, Takayuki ; Nishikawa, Tomoaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-3e346ab7c695e8815c54f24c309267829ad954c345a7f36f07e15b33aca348d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>covalent BTK inhibitor</topic><topic>ibrutinib</topic><topic>Japanese patients</topic><topic>Letter to the Editor</topic><topic>mantle cell lymphoma</topic><topic>phase II clinical trial</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maruyama, Dai</creatorcontrib><creatorcontrib>Nagai, Hirokazu</creatorcontrib><creatorcontrib>Fukuhara, Noriko</creatorcontrib><creatorcontrib>Kitano, Toshiyuki</creatorcontrib><creatorcontrib>Ishikawa, Takayuki</creatorcontrib><creatorcontrib>Nishikawa, Tomoaki</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Clinical and Experimental Hematopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maruyama, Dai</au><au>Nagai, Hirokazu</au><au>Fukuhara, Noriko</au><au>Kitano, Toshiyuki</au><au>Ishikawa, Takayuki</au><au>Nishikawa, Tomoaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma</atitle><jtitle>Journal of Clinical and Experimental Hematopathology</jtitle><addtitle>J Clin Exp Hematopathol</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>59</volume><issue>2</issue><spage>98</spage><epage>100</epage><pages>98-100</pages><issn>1346-4280</issn><eissn>1880-9952</eissn><pub>The Japanese Society for Lymphoreticular Tissue Research</pub><pmid>31257351</pmid><doi>10.3960/jslrt.19006</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1346-4280
ispartof Journal of Clinical and Experimental Hematopathology, 2019, Vol.59(2), pp.98-100
issn 1346-4280
1880-9952
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6661957
source Open Access: PubMed Central
subjects covalent BTK inhibitor
ibrutinib
Japanese patients
Letter to the Editor
mantle cell lymphoma
phase II clinical trial
title Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A15%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Final%20analysis%20of%20a%20phase%20II%20study%20of%20ibrutinib%20in%20Japanese%20patients%20with%20relapsed/refractory%20mantle%20cell%20lymphoma&rft.jtitle=Journal%20of%20Clinical%20and%20Experimental%20Hematopathology&rft.au=Maruyama,%20Dai&rft.date=2019-01-01&rft.volume=59&rft.issue=2&rft.spage=98&rft.epage=100&rft.pages=98-100&rft.issn=1346-4280&rft.eissn=1880-9952&rft_id=info:doi/10.3960/jslrt.19006&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_6661957%3C/pubmedcentral_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c529t-3e346ab7c695e8815c54f24c309267829ad954c345a7f36f07e15b33aca348d83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/31257351&rfr_iscdi=true